BACKGROUND: Identification of risk factors for reduced asthma control could improve the understanding and treatment of asthma. A promoter polymorphism in the 5-lipoxygenase gene affects gene expression and response to asthma therapy, but its impact on disease control remains unclear. OBJECTIVE: We sought to determine if the ALOX5 promoter SP1 tandem repeat polymorphism was associated with changes in cysteinyl leukotriene production, lung function, airway inflammation and asthma control score. METHODS: We analysed 270 children, 6- to 17-years old, with poorly controlled asthma enrolled in a 6-month clinical trial (NCT00604851). In secondary analysis, we associated the ALOX5 promoter SP1 tandem repeat polymorphism genotype (rs59439148) with asthma outcomes using both additive and recessive genetic models. We evaluated FEV1 percent predicted, symptom control, exhaled nitric oxide and urinary LTE4 levels. RESULTS: Of all children, 14.8% (40/270) (and 28% (38/135) of African Americans) carried two non-5-repeat variant alleles of rs59439148. Children who were homozygous for variant alleles had significantly higher urinary LTE4 levels (38 vs. 30 nmol/mol creatinine, P = 0.0134), significantly worse FEV1% predicted (84 vs. 91, P = 0.017) and a trend towards worse asthma control. FEV1% predicted values were significantly negatively correlated with urinary LTE4 (r = -0.192, P = 0.009). CONCLUSION AND CLINICAL RELEVANCE: Carrying two copies of a minor variant ALOX5 promoter SP1 tandem repeat allele contributes to increased cysLT exposure as determined by urinary LTE4 levels, reduced lung function and potentially worse asthma control. ALOX5 promoter SP1 tandem repeat genotype may be a risk factor for worse asthma outcomes.
BACKGROUND: Identification of risk factors for reduced asthma control could improve the understanding and treatment of asthma. A promoter polymorphism in the 5-lipoxygenase gene affects gene expression and response to asthma therapy, but its impact on disease control remains unclear. OBJECTIVE: We sought to determine if the ALOX5 promoter SP1 tandem repeat polymorphism was associated with changes in cysteinyl leukotriene production, lung function, airway inflammation and asthma control score. METHODS: We analysed 270 children, 6- to 17-years old, with poorly controlled asthma enrolled in a 6-month clinical trial (NCT00604851). In secondary analysis, we associated the ALOX5 promoter SP1 tandem repeat polymorphism genotype (rs59439148) with asthma outcomes using both additive and recessive genetic models. We evaluated FEV1 percent predicted, symptom control, exhaled nitric oxide and urinary LTE4 levels. RESULTS: Of all children, 14.8% (40/270) (and 28% (38/135) of African Americans) carried two non-5-repeat variant alleles of rs59439148. Children who were homozygous for variant alleles had significantly higher urinary LTE4 levels (38 vs. 30 nmol/mol creatinine, P = 0.0134), significantly worse FEV1% predicted (84 vs. 91, P = 0.017) and a trend towards worse asthma control. FEV1% predicted values were significantly negatively correlated with urinary LTE4 (r = -0.192, P = 0.009). CONCLUSION AND CLINICAL RELEVANCE: Carrying two copies of a minor variantALOX5 promoter SP1 tandem repeat allele contributes to increased cysLT exposure as determined by urinary LTE4 levels, reduced lung function and potentially worse asthma control. ALOX5 promoter SP1 tandem repeat genotype may be a risk factor for worse asthma outcomes.
Authors: J W Woods; J F Evans; D Ethier; S Scott; P J Vickers; L Hearn; J A Heibein; S Charleson; I I Singer Journal: J Exp Med Date: 1993-12-01 Impact factor: 14.307
Authors: Jason E Lang; Edward B Mougey; Md Jobayer Hossain; Floyd Livingston; P Babu Balagopal; Scott Langdon; John J Lima Journal: Ann Am Thorac Soc Date: 2019-05
Authors: Jason E Lang; Anne M Fitzpatrick; David T Mauger; Theresa W Guilbert; Daniel J Jackson; Robert F Lemanske; Fernando D Martinez; Robert C Strunk; Robert S Zeiger; Wanda Phipatanakul; Leonard B Bacharier; Jacqueline A Pongracic; Fernando Holguin; Michael D Cabana; Ronina A Covar; Hengameh H Raissy; Monica Tang; Stanley J Szefler Journal: J Allergy Clin Immunol Date: 2017-12-19 Impact factor: 10.793
Authors: Jelle Folkerts; Frank Redegeld; Gert Folkerts; Bart Blokhuis; Mariska P M van den Berg; Marjolein J W de Bruijn; Wilfred F J van IJcken; Tobias Junt; See-Ying Tam; Stephen J Galli; Rudi W Hendriks; Ralph Stadhouders; Marcus Maurer Journal: Allergy Date: 2020-04-24 Impact factor: 13.146
Authors: William Vizuete; Kenneth G Sexton; Hang Nguyen; Lisa Smeester; Kjersti Marie Aagaard; Cynthia Shope; Barry Lefer; James H Flynn; Sergio Alvarez; Mathew H Erickson; Rebecca C Fry Journal: Environ Health Insights Date: 2016-02-18
Authors: Miles D Thompson; Valerie Capra; Mark T Clunes; G E Rovati; Jana Stankova; Mary C Maj; David L Duffy Journal: Front Pharmacol Date: 2016-12-01 Impact factor: 5.810
Authors: Chinedu Nwokoro; Hitesh Pandya; Stephen Turner; Sandra Eldridge; Christopher J Griffiths; Tom Vulliamy; David Price; Marek Sanak; John W Holloway; Rossa Brugha; Lee Koh; Iain Dickson; Clare Rutterford; Jonathan Grigg Journal: Lancet Respir Med Date: 2014-09-08 Impact factor: 30.700